Applications were invited from early-stage healthtech ventures with solutions to problems faced by healthcare systems globally. The call closed at midnight on 12th November 2021.
QUESTIONS ABOUT FUTURE INVESTMENT CALLS? EMAIL: firstname.lastname@example.org
OUR INVESTMENT CALL
MedCity has partnered with Spex Capital to source, evaluate and fund early-stage healthtech ventures and accelerate their route to commercialisation. This exclusive partnership will support several calls for innovative companies seeking investment over the next two years.
The call is targeted at innovative health tech companies seeking Seed or Series A investment. Spex Capital will look to invest up to a max of £5 million per target company. The average ticket is expected to between £500k and £2 million but smaller tickets will be welcome. Successful applicants will also benefit from access to advisory teams with deep sector experience.
Leading from the MedCity side to source and evaluate viable candidates are COO Nicki Bromwich and Programme Lead Sakura Holloway. Nicki Bromwich has 30 years’ experience as a clinician in the NHS and served as Head of Commercial Development at Oxford AHSN before joining MedCity. Sakura Holloway is an IP and commercial strategist in the biotech sector with a technical background in molecular biology.
ABOUT SPEX CAPITAL
Founded in 2021 by serial healthtech entrepreneur Claudio D’Angelo, London-based Spex Capital already has a portfolio of six high-growth digital health and medtech companies. The venture firm launched with a team of sixteen, comprising seven investment team members, seven senior advisors and two venture partners. Founder and managing director Claudio D’Angelo leads the call from the Spex Capital side together with senior investment team member Filippo Falaschi.